ATE253929T1 - Verwendung von löslichem rezeptor für fortgeschrittene glykosilierung-endprodukte (srage) zur unterdrückung der beschleunigter atheriosklerose - Google Patents

Verwendung von löslichem rezeptor für fortgeschrittene glykosilierung-endprodukte (srage) zur unterdrückung der beschleunigter atheriosklerose

Info

Publication number
ATE253929T1
ATE253929T1 AT98939876T AT98939876T ATE253929T1 AT E253929 T1 ATE253929 T1 AT E253929T1 AT 98939876 T AT98939876 T AT 98939876T AT 98939876 T AT98939876 T AT 98939876T AT E253929 T1 ATE253929 T1 AT E253929T1
Authority
AT
Austria
Prior art keywords
soluble receptor
subject
atheriosclerosis
srage
end products
Prior art date
Application number
AT98939876T
Other languages
German (de)
English (en)
Inventor
David Stern
Ann Marie Schmidt
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of ATE253929T1 publication Critical patent/ATE253929T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Producing Shaped Articles From Materials (AREA)
  • Seasonings (AREA)
  • Special Spraying Apparatus (AREA)
AT98939876T 1997-08-05 1998-08-05 Verwendung von löslichem rezeptor für fortgeschrittene glykosilierung-endprodukte (srage) zur unterdrückung der beschleunigter atheriosklerose ATE253929T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/905,709 US7101838B2 (en) 1997-08-05 1997-08-05 Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
PCT/US1998/016303 WO1999007402A1 (en) 1997-08-05 1998-08-05 METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS

Publications (1)

Publication Number Publication Date
ATE253929T1 true ATE253929T1 (de) 2003-11-15

Family

ID=25421326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939876T ATE253929T1 (de) 1997-08-05 1998-08-05 Verwendung von löslichem rezeptor für fortgeschrittene glykosilierung-endprodukte (srage) zur unterdrückung der beschleunigter atheriosklerose

Country Status (11)

Country Link
US (2) US7101838B2 (https=)
EP (1) EP1011706B1 (https=)
JP (2) JP4426090B2 (https=)
AT (1) ATE253929T1 (https=)
AU (1) AU758252B2 (https=)
CA (1) CA2299467A1 (https=)
DE (1) DE69819751T8 (https=)
DK (1) DK1011706T3 (https=)
ES (1) ES2210800T3 (https=)
PT (1) PT1011706E (https=)
WO (1) WO1999007402A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
EP1307219A4 (en) * 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US7087632B2 (en) 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
CN1494425B (zh) 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
JP3837494B2 (ja) 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
JP4481011B2 (ja) 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2006012415A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
KR20070057818A (ko) * 2004-08-03 2007-06-07 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
JP5188804B2 (ja) * 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
US20060084145A1 (en) 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses
MX2007011411A (es) * 2005-03-17 2007-11-13 Univ Columbia Interaccion rage/diaphanous y composiciones relacionadas y metodos.
AU2006327353B2 (en) * 2005-12-23 2011-11-24 Gcoder Systems Ab Positioning pattern
KR20080105066A (ko) * 2006-02-09 2008-12-03 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
AU2007248784B2 (en) 2006-05-05 2013-11-21 Vtv Therapeutics Llc RAGE fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
EP2158210B1 (en) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage fusion proteins
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) * 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
WO2013103688A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human soluble receptors for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CA2903946A1 (en) * 2013-03-08 2014-09-12 Zora Biosciences Oy Non-high density lipoprotein derived cvd markers
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2022089639A1 (zh) * 2020-10-30 2022-05-05 深圳普罗吉医药科技有限公司 人血清白蛋白在治疗疾病中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
WO1992010579A1 (fr) 1990-12-07 1992-06-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha PROCEDE DE PRODUCTION DE D-α-AMINOACIDES
CN1134803A (zh) 1996-01-24 1996-11-06 沈阳市大东副食品商场 乘车游乐自选购物系统
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
EP1307219A4 (en) 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF

Also Published As

Publication number Publication date
US20070099829A1 (en) 2007-05-03
AU8823998A (en) 1999-03-01
EP1011706A4 (en) 2001-10-17
JP2001513511A (ja) 2001-09-04
PT1011706E (pt) 2004-04-30
EP1011706A1 (en) 2000-06-28
DE69819751D1 (de) 2003-12-18
DK1011706T3 (da) 2004-03-22
HK1030742A1 (en) 2001-05-18
US20010039256A1 (en) 2001-11-08
WO1999007402A1 (en) 1999-02-18
US7101838B2 (en) 2006-09-05
JP4426090B2 (ja) 2010-03-03
DE69819751T2 (de) 2004-09-30
DE69819751T8 (de) 2005-01-05
JP2010065040A (ja) 2010-03-25
US7494972B2 (en) 2009-02-24
CA2299467A1 (en) 1999-02-18
AU758252B2 (en) 2003-03-20
JP4976475B2 (ja) 2012-07-18
EP1011706B1 (en) 2003-11-12
ES2210800T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE253929T1 (de) Verwendung von löslichem rezeptor für fortgeschrittene glykosilierung-endprodukte (srage) zur unterdrückung der beschleunigter atheriosklerose
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
DE69123334D1 (de) Schlangenverwalterverfahren für ein elektronisches Mitteilungssystem
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
DE69811790D1 (de) Ableitung von Prozessmodellen aus Rechnungsprüfvorgängen für Systeme zur Verwaltung von Arbeitsflüssen
DE69723860D1 (de) VERFAHREN ZUR BESTIMMUNG VON IgE
DE58906257D1 (de) Verfahren zur Abtrennung von Störelementen aus Wertmetall-Elektrolytlösungen.
DE69530800D1 (de) VERWENDUNG VON La/Nd-SPINELZUSAMMENSETZUNGEN FÜR PASSIVATION VON METAlLEN IM FCC-VERFAHREN
DE69128924D1 (de) System zur Unterdrückung der Verzögerungsverzerrung für ein ATM-Kommunikationssystem
DE3765805D1 (de) Verfahren zur brikettierung von kohle.
DE69838472D1 (de) Signalverarbeitungsverfahren für ein analoges Bildsignal
EP0894565A3 (de) Abbundanlage
DE3871226D1 (de) Verfahren zur abschaetzung von scherwellenreflexionsmesswerten aus erfassten kompressionswellenreflexionsmesswerten.
EP0809199A3 (en) Clock skew insensitive scan chain reordering
ATE170631T1 (de) Verfahren und zusammensetzung zur verminderung der effekte von endogener alkalischer phosphatase
FI885312L (fi) Menetelmä spesifisesti sitovan proteiinin ja vastaavan sidottavan aineen välisen reaktion yhden tai useamman komponentin määrittämiseksi koenäytteestä käyttäen ainakin yhtä leimattua komponenttia, menetelmä leimatun komponentin valmistamiseksi sekä koepakkaus.......
DE69712878D1 (en) Phosphatasemodulator
DE3480928D1 (de) 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.
DE69810058D1 (de) Faserführender Keil für Karden
DE69635739D1 (de) Verwendung eines sec-abhängigen sekretionssystems zur sekretion von proteinen, welche gewöhnlich durch ein sec-unabhängiges sekretionssystem sekretiert werden
NO884169D0 (no) Fremgangsmaate for frembringelse av skjaereboelgerefleksjonsinformasjon ut fra informasjon om kompresjonsboelgerefleksjon.
DE69605105D1 (de) Verfahren zur herstellung von 4,6-dimethoxy-2-((phenoxycarbonyl)amino)-pyrimidin
ES2175842T3 (es) Antagonistas de kv2.1.
DE3871473D1 (de) Verfahren zum schaetzen von scherwellenreflektionsdaten von gemessenen kompressionswellenreflektionsdaten.
Chehayeb et al. Apportionment delay method: Is there only one solution?

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1011706

Country of ref document: EP